The first observational study published in this Thursday’s issue The Lancet On the results of vaccination against corona virus produced by Pfizer and Biotech vaccine in Israel Ensures more than 95% protection against infections and hospitalization, The level of performance decreases when a person receives only one of two levels.
More than half of the adult population vaccinated with two injections (58%) A major analysis to understand the effect of reducing and controlling the spread of the virus and subsequent expansion measures. That is why the world is watching the results carefully, while at the same time Israel was able to normalize the measures based on the successful vaccination campaign.
The study, the largest study ever conducted by Pfizer and Israeli government scientists, highlights the “public health benefits of a national vaccination program”, which is “the main driver of the fall in infections. By Govt-19”.
However, The same study warns of “caution when generalizing these results to other countries”, This is because the speed of vaccination programs and the evolution of the infection vary, in addition to observing the circulation of other types.
The text is a version published and reviewed by other independent scientists of the first results released by Pfizer and the Israeli Ministry of Health in March. This is in line with the health data collected from January 24 to April 3, with 72% of people over the age of 16 (approximately 5 million people) and 90% of people over the age of 65 in Israel receiving their two Pfizer / Bioentech vaccine levels. The analysis focuses on the effectiveness of the vaccine against the dominant English variant (called P.1.1.7) in the country.
This observation takes into account national surveillance data from the first 4 months of the vaccination campaign, the SARS-CoV-2 results confirmed by Infections and Laboratories, and the immunization of Israeli residents aged 16 years and over.
Another data that is reflected in the output, development Seven days after the second dose it is “very effective”: Protects 95.3% of infections, 97.2% of hospitalizations and 96.7% of deaths. These safety levels are the same for people over 85 years of age.
However, the study marks the first “blow” fall. When people have only one of two levels, the decline is noticeable: 57.7% against infection, 75.7% against hospitalization and 77% against death. In those over 16 years of age.
This real-life research “shows the importance of a complete vaccine for adults”, with two dimensions, the authors conclude. For them, a single dose may also provide shorter protection, especially as more resistant varieties appear to be vaccinated.
At the time of analysis, there were 232,268 confirmed COVID-19 infections in Israel (with 4,481 severe infections and 1,113 deaths), and 95% of the samples analyzed were of English variant.
The researchers point out that it is not possible to study the effectiveness of the vaccine against the South African variant. In February, the first large-scale study conducted in Israel (1.2 million people) and published in the journal NEJM reached similar results.
The campaign to achieve Israeli immunity began in January 2021 in an environment that reached a maximum of 10,213 daily infections. By the end of December, a harsh imprisonment that lasted until March had already been ordered. Currently, the country is back to normal even without synchro straps and social distances.